Risk of Pure Red Cell Aplasia in Patients With Hepatitis C Receiving Antiviral Therapy and an Erythropoiesis-Stimulating Agent
- 1 February 2014
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 12 (2) , 341-345
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- 1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERSJournal of Hepatology, 2012
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver DiseasesHepatology, 2011
- Pure red‐cell aplasia associated with pegylated interferon‐alpha‐2b plus ribavirinAmerican Journal of Hematology, 2008
- Pure Red Cell Aplasia Induced by Erythropoiesis-Stimulating AgentsClinical Journal of the American Society of Nephrology, 2008
- Peginterferon and Ribavirin for Chronic Hepatitis CNew England Journal of Medicine, 2006
- Ribavirin-Induced Pure Red-Cell Aplasia during Treatment of Chronic Hepatitis CNew England Journal of Medicine, 2004
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Interferon-ɑ-induced pure red cell aplasia following chronic myelogenous leukemiaAnti-Cancer Drugs, 2001
- Pure red cell aplasia in a patient with chronic granulocytic leukaemia treated with interferon-αClinical and Laboratory Haematology, 2000
- Pure Red Cell Aplasia Responsive to Interferon-α in a Patient with Hepatitis C Virus InfectionActa Haematologica, 1998